コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 markers of filtration (serum creatinine and cystatin C).
2 ment (R(2) = 0.989 for CRP; R(2) = 0.939 for cystatin C).
3 l, 0.8-4.1] per standard deviation change in cystatin C).
4 cells (DC) are the predominant producers of cystatin C.
5 established renal function indices eGFR and cystatin C.
6 rmined by longitudinal measurements of serum cystatin C.
7 tory activity or amyloidogenic properties of cystatin C.
8 ar filtration rate (GFR), estimated GFR, and cystatin C.
9 a traditional sandwich immunoassay for serum cystatin C.
10 han when cells were incubated with wild-type cystatin C.
11 rovement in reclassification with the use of cystatin C.
12 s illustrated by incubating cells with W106F-cystatin C.
13 We estimated GFR using cystatin C.
14 inine, 24% did not have CKD by either ACR or cystatin C.
15 inine, 3863 (16%) had CKD detected by ACR or cystatin C.
16 terminal pro-B type natriuretic peptide, and cystatin C.
17 ylarginine, high-sensitivity troponin T, and cystatin C.
18 equation based on both plasma creatinine and cystatin C.
19 for legumain is 100-fold higher than that of cystatin C.
20 are never labelled with anti-TDP-43 or anti-cystatin C.
21 explaining 2.8% of the observed variation in cystatin C.
22 data for amyloids from either cystatin B or cystatin C.
23 rer prognosis within cohorts of high and low cystatin C.
24 proteinuria, and a 6-fold increase in serum cystatin-C.
25 ctive treatment's effect and EF on change in cystatin-C.
28 ct to limits of detection (CRP, 0.10 mug/mL; cystatin C, 0.003 mug/mL) and coefficients of variation
29 he extracellular cysteine protease inhibitor cystatin C, 12 variants of the protein were produced and
31 rs911119 was associated with decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p =
32 l relative risk for CVD of 1.00 per doubling cystatin C (95% CI: 0.82 to 1.22; p = 0.994), which was
33 factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence interval [CI]: 1.56 to 2.13;
34 alysis, we examined the relationship between cystatin C (a marker of renal function) and PASP and pot
35 al serum potassium levels and measurement of cystatin C, a non-creatinine measure of kidney function.
37 , we developed estimating equations based on cystatin C alone and in combination with creatinine in d
39 lculated by the measurement of creatinine or cystatin C alone or in combination with creatinine, with
40 .9-2.7) for participants with CKD defined by cystatin C alone, and 3.0 (95% CI, 2.4-3.7) for particip
48 howed increased levels and distinct forms of cystatin C amyloid that were not present in WT mice.
50 L68Q epididymal fluid that was depleted of cystatin C amyloids, however, did not impair the motilit
51 cohorts (n = 76,481) with 37,126 measures of cystatin C and added genetic data from 43 studies (n = 2
54 ult ICU survivors, we compared ICU discharge cystatin C and creatinine and their association with 1-y
56 s of estimating GFR, equations based on both cystatin C and creatinine do not predict mortality as we
57 ge in the C statistic was noted with FRSVs + cystatin C and FRSVs + creatinine compared with FRSVs al
61 highly ordered, domain-swapped assemblies of cystatin C and that the oligomers could not build larger
63 Here we aimed to investigate if uptake of cystatin C and the related inhibitor cystatin E/M occur
65 y cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and ala
66 for those with CKD defined by creatinine and cystatin C, and 5.6 (95% CI, 3.9-8.2) for those with CKD
68 er adjustment for GFR, levels of creatinine, cystatin C, and beta trace protein, each remained direct
69 immunosorption, using immobilized monomeric cystatin C, and elution from columns with immobilized cy
71 Four markers (albumin, beta-2-microglobulin, cystatin C, and osteopontin) were undetectable in most A
73 isease Epidemiology Collaboration creatinine-cystatin C, and urate and high-sensitivity C-reactive pr
75 Conversely, lower creatinine relative to cystatin C appeared to confer adverse prognosis, confoun
76 herapeutics targeted at lowering circulating cystatin C are unlikely to be effective in preventing CV
77 implications for the diagnostic use of serum cystatin C as a marker of kidney function during inflamm
79 fication improvement with the measurement of cystatin C, as compared with creatinine, was 0.23 (95% c
80 FR to a higher value with the measurement of cystatin C, as compared with creatinine, was associated
82 mination of renal function by creatinine and cystatin C-based eGFR revealed decreasing eGFRs in the d
83 (2) of body-surface area was higher with the cystatin C-based eGFR than with the creatinine-based eGF
85 tly associated with childhood kidney volume, cystatin C-based eGFR, or the risk of microalbuminuria.
86 inine-based equation only, 2% had CKD by the cystatin C-based equation only, and 4% had CKD by both e
90 3.51) in models adjusted for age, sex, race, cystatin C-based estimated glomerular filtration rate, b
97 lable creatinine at baseline (n=17 951), and cystatin C-based glomerular filtration rate was estimate
98 our knowledge, no previous studies have used cystatin C-based measures of the estimated glomerular fi
99 IS1: creatinine-based; BIS2: creatinine- and cystatin C-based) with other estimating equations and de
100 0% (creatinine-based) and approximately 50% (cystatin c-based), indicating that 90% of the estimation
101 We further assessed the impact of using cystatin-C-based eGFR in risk prediction equations for C
102 and international guidelines recommend that cystatin-C-based estimates of GFR be used to confirm or
105 sC5b-9) and renal injury markers (clusterin, cystatin-C, beta2-microglobulin, and liver fatty acid bi
106 red childhood kidney volumes, creatinine and cystatin C blood levels, microalbuminuria, BP, and eGFR.
110 m2, calculated using the combined creatinine-cystatin C CKD-Epidemiology Collaboration Equation.
111 omarkers (haemoglobin, cTn-hs, and GDF-15 or cystatin C/CKD-EPI) was internally and externally valida
112 ss than 60 mL/min/1.73 m when estimated from cystatin C compared with glomerular filtration rate esti
113 baseline and 0- to 24-week changes in plasma cystatin C concentration with measures of vascular disea
117 ation rate (eGFR) using serum creatinine and cystatin C concentrations, and microalbuminuria using ur
120 ence, the authors studied the association of cystatin C, creatinine-based estimated glomerular filtra
121 gh-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-sensitivity C-reactive protein
123 tion rate (GFR) equations incorporating both cystatin C (CysC) and serum creatinine (Creat) in living
127 t renal function measures are imperfect, and cystatin C (CysC) is promoted as a better marker of glom
130 ins and their principal endogenous inhibitor cystatin C (CystC) may favor proteolysis in the pathogen
131 the legumain binding region (N39K- and N39A-cystatin C) decreased the internalization and (R24A,R25A
132 1 promotes fibrosis by driving the effective cystatin C-dependent inhibition of extracellular matrix-
133 ) in young and middle-aged adults who have a cystatin C-derived estimated glomerular filtration rate
134 D) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate
137 These could be used to selectively remove cystatin C dimers from biological fluids containing both
138 s, and of the potential legumain inhibitors, cystatin C, E/M, and F, cystatin C was the one mainly pr
139 ed GFR estimated from creatinine (eGFR(Cr)), cystatin C (eGFR(Cys)), or both (eGFR(Cr+Cys)) with ioth
143 imated by serum creatinine (eGFRcrea), serum cystatin c (eGFRcys) and CKD (eGFRcrea < 60 ml/min/1.73
145 GFR should be calculated and reported using cystatin C (eGFRcys) and serum creatinine (eGFRcr-cys) o
146 d GFR estimated from creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys) at baseli
147 estimated by serum creatinine (eGFRcrea) and cystatin C (eGFRcys), and CKD (eGFRcrea < 60 ml/min/1.73
148 diagnostic performance of CKD-EPI creatinine-cystatin C equation (2012) in patients with cirrhosis wa
149 Performance of the new CKD-EPI creatinine-cystatin C equation (2012) was superior to previous crea
150 73 m(2) with the creatinine equation and the cystatin C equation (P=0.07 and P=0.05), respectively.
151 r the BIS2 equation (11.6%), followed by the cystatin C equation 2 (15.1%) proposed by the Chronic Ki
153 ubjects, GFR estimated by CKD-EPI creatinine-cystatin C equation differed from the mGFR by more than
154 te the performance of the CKD-EPI creatinine-cystatin C equation in subjects with cirrhosis, we compa
156 In the validation data set, the creatinine-cystatin C equation performed better than equations that
157 and "accuracy" of the new CKD-EPI creatinine-cystatin C equation to that of 24-hour urinary creatinin
160 ongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function e
163 y C-reactive protein greater than 3.0 mg/dL, cystatin C >/=1.11 mg/dL, estimated glomerular filtratio
164 tive protein, urinary albumin excretion, and cystatin-C had similar risk for new-onset HF between bot
166 from serum concentrations of creatinine and cystatin C has been refined using cross-sectional data f
168 ne the extent to which the addition of serum cystatin C improves glomerular filtration rate (GFR) est
169 vation and inflammation were associated with cystatin C in a multivariable model independent of creat
170 l variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, isc
171 s 6.4% (P < .001) after adding estimated GFR cystatin C in fully adjusted models with estimated GFR c
178 of GFR-estimating equations with and without cystatin C, including the modification of diet in renal
179 ile serum creatinine fell at 12 hours, serum cystatin C increased, suggestive of decreased creatinine
180 , galectin-3, midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.
181 prostate cancer cells corroborated that the cystatin C internalization is generally relevant and con
184 iological studies show that high circulating cystatin C is associated with risk of cardiovascular dis
185 ndelian randomization to investigate whether cystatin C is causally related to CVD in the general pop
191 he extracellular concentration of inhibitory cystatin C is thus partly dependent on the abundance of
194 dominant disorder in which a variant form of cystatin C (L68Q) readily forms amyloid deposits in cere
195 714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18
196 618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.
197 ely associated with childhood creatinine and cystatin C levels (all P values <0.05), but did not asso
204 tudy participants, hsCRP, IL-6, D-dimer, and cystatin C levels were 50%, 152%, 94%, and 27% higher, r
205 ated on the basis of creatinine (eGFRcr) and cystatin C levels were assessed in </=1735 participants
207 After adjustment for both creatinine and cystatin C levels, higher discharge creatinine was then
208 easured GFR from standardized creatinine and cystatin C levels, sex, and age in the learning sample;
210 -treated groups had a 35% reduction in serum cystatin-C levels and reduced crescent numbers compared
211 allel with Elmo1, as do the plasma levels of cystatin C, lipid peroxides, and TGFbeta1, and erythrocy
212 munodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glome
214 imilarly, both in patients with high and low cystatin C (median cut-off), higher plasma NGAL levels w
215 )=39.1[height (m)/Scr (mg/dl)](0.516) x [1.8/cystatin C (mg/L)](0.294)[30/BUN (mg/dl)](0.169)[1.099](
216 ed GFR, the formula with both creatinine and cystatin C, namely, CKD-epidemiology cr-cys, outperforme
217 phosphatase, gamma-glutamyl transpeptidase, cystatin C, neutrophil gelatinase-associated lipocalin,
219 n rate (GFR) determined by creatinine and by cystatin C of either <60 or >/=60 mL/min/1.73 m(2) and A
220 C, and elution from columns with immobilized cystatin C oligomers, oligomer-specific antibodies were
224 only; 3.23 (95% CI 1.84 to 5.67) for CKD by cystatin C only; and 1.93 (95% CI 1.27 to 2.92) for CKD
227 tudied the incremental value of adding serum cystatin C or creatinine to the Framingham risk score va
228 ted using equations that incorporated either cystatin C or creatinine, and CKD was defined by estimat
232 lternative biomarkers (haematocrit, cTnI-hs, cystatin C, or creatinine clearance) also outperformed t
233 not increase albuminuria, proteinuria, serum cystatin C, or serum creatinine levels in TxNIP(-/-) mic
234 plasma biomarkers of renal injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloprot
235 = .026, area under ROC curve [AUC] = 0.818), cystatin C (P = .033, AUC = 0.805), and creatinine (P =
236 le risk prediction model, eGFR (P=0.616) and cystatin C (P=0.937) were no longer associated with mort
238 bining a functional damage biomarker (plasma cystatin C [pCysC]) with a tubular damage biomarker (uri
239 8.30-21.2); Pnoninferiority = 0.0011], serum cystatin C (Pnoninferiority < 0.0001), serum creatinine
240 ons, little is known about the regulation of cystatin C production, dimerization, and secretion.
241 of cystatin C under the control of the mouse cystatin C promoter were unable to generate offspring, s
242 n decline of eGFR (Ptrend<0.001) and rise of cystatin C (Ptrend=0.01) and creatinine (Ptrend<0.001) l
244 atinine measure but detected by both ACR and cystatin C (rate per 1000 person-years, 6.4; 95% CI, 3.6
245 ation coefficient, serum creatinine-to-serum cystatin C ratio was found to be the best performer in t
250 he control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vitamin K-Dependent Protein S[
254 ss or diet), or interference with the assay, cystatin C should be measured and estimated GFR should b
256 ation, we use redox experiments of monomeric cystatin C, stabilized against domain swapping by an int
257 atients had lower levels of cardiotrophin-1, cystatin C, syndecan-4, and N terminal-probrain natriure
260 , these results suggest that the addition of cystatin C to creatinine to estimate GFR may improve ide
263 neutrophil gelatinase-associated lipocalin, cystatin C, trefoil factor 3, tissue inhibitor of metall
264 L68Q) that express the human L68Q variant of cystatin C under the control of the mouse cystatin C pro
267 hereditary cystatin C amyloid angiopathy, a cystatin C variant is deposited in arterial walls and ca
269 ne eGFR was 54+/-20 mL/min per 1.73 m2, mean cystatin C was 11.2 (7.7-16.2) mg/L, and median plasma N
274 ysis adjusted for age, sex, and comorbidity, cystatin C was near-linearly associated with increased m
280 ge glomerular filtration rate estimated from cystatin C well matched follow-up chronic kidney disease
281 mated glomerular filtration rate (eGFR), and cystatin C were assessed in 562 patients with heart fail
283 in (hsCRP), interleukin (IL)-6, D-dimer, and cystatin C were compared in 494 HIV-infected individuals
288 L9G,V10G)-, (R8G,L9G,V10G,W106G)-, and W106G-cystatin C) were internalized to a very low extent compa
289 binding protein, urinary interleukin-18, and cystatin C) were measured in 1,635 unselected emergency
290 n factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before TAVR and in 100 sex-mat
291 eded in a number of assays, such as that for cystatin C, where a 1.5-fold increase in concentration m
292 ration equation, the eGFR was estimated from cystatin C with all available samples per participant ex
293 extent comparable with the W106F variant of cystatin C with optimal uptake properties and resulting
295 ed vesicular co-localization of internalized cystatin C with the lysosomal marker proteins cathepsin
296 eaker associations than equations using only cystatin C (with or without age, race, and gender).
297 id not provide evidence for a causal role of cystatin C, with a causal relative risk for CVD of 1.00
298 terminal pro-B-type natriuretic peptide, and cystatin C, with longer QRS interval, with lower heart r
300 ecreased the internalization and (R24A,R25A)-cystatin C, with substitutions of charged residues not i
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。